Trials / Enrolling By Invitation
Enrolling By InvitationNCT06737354
Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).
An Exploratory Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).
- Status
- Enrolling By Invitation
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (estimated)
- Sponsor
- InnoVec Biotherapeutics Inc. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of IVB103 injection in subjects with nAMD.
Detailed description
This is an open-label, non-randomized, multi-center dose escalation study. One eye of each participant will receive a single IVB103 injection by intravitreal injection. Participants will be followed for 52 weeks after which they will continue to be followed for up to 5 years after enrollment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | IVB103 Injection（Low dose） | Single intravitreal injection |
| GENETIC | IVB103 Injection（Intermediate dose） | Single intravitreal injection |
| GENETIC | IVB103 Injection（High dose） | Single intravitreal injection |
Timeline
- Start date
- 2025-04-22
- Primary completion
- 2027-12-31
- Completion
- 2031-12-31
- First posted
- 2024-12-17
- Last updated
- 2025-04-30
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06737354. Inclusion in this directory is not an endorsement.